Genetics startup Agilis names industry vet Zorich CEO

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Genetics startup Agilis names industry vet Zorich CEO

New York startup Agilis Biotherapeutics named George Zorich its new CEO. Before taking on the lead role at the new developer of DNA-based treatments for genetic diseases, Zorich served for over 30 years in the industry. Most recently, he was president of Bioniche Pharma, which was acquired by Mylan ($MYL). He has also been president of U.S. operations for injectables maker Sabex--acquired by Sandoz--as well as president of Globexpharma and General Injectables and Vaccines, which was acquired by Henry Schein. He also held roles at Boehringer Ingelheim and Eli Lilly ($LLY) early in his career. "I'm delighted to be joining this team of highly regarded researchers and business leaders working in collaboration with Intrexon ($XON) to potentially develop novel approaches to treating rare genetic diseases with synthetic biology," Zorich said in a statement. Release

Agilis Biotherapeutics
George Zorich will serve as Agilis' CEO.


ImmunoGen
David Johnston was named executive vice president.


Biotech

ImmunoGen ($IMGN) appointed David Johnston as executive vice president and chief financial officer. Johnston joins ImmunoGen from Aveo Pharmaceuticals ($AVEO), where he was the CFO. Release

> The CEO of Star Scientific, Jonnie Williams, has stepped down amid allegations from the FDA that the company is illegally marketing its dietary supplements. Story

> Wendell Wierenga has joined Ocera Therapeutics' ($OCRX) board of directors. Wierenga presently serves as executive vice president, research and development at Santarus. Release

Advanced Cell Technology appointed Dr. Eddy Anglade to the newly created position of executive vice president of clinical development. Release

Pharma

> Rakesh Bamzai joined Mylan ($MYL) as president of its India commercial and emerging markets arm. Prior to Mylan, Bamzai was president of marketing at Biocon. Release | Story

Pozen appointed Dennis McNamara to be the company's senior vice president and chief business officer. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.